Overcoming the Declining Trends in Innovation and Investment in Cardiovascular Therapeutics
Eroom’s law (Moore’s law spelled backwards), describes adverse trends towards declining innovation and rising costs of drug development over the last several decades. Therapeutics for cardiovascular diseases (CVD) appear to have been particularly sensitive to these trends. Thirty-three percent fewer...
Main Author: | Gail A. Van Norman, MD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-10-01
|
Series: | JACC: Basic to Translational Science |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2452302X17302231 |
Similar Items
-
Drugs and Devices
by: Gail A. Van Norman, MD
Published: (2016-08-01) -
Drugs, Devices, and the FDA: Part 1
by: Gail A. Van Norman, MD
Published: (2016-04-01) -
Trends in FDA drug approvals over last 2 decades: An observational study
by: Angelika Batta, et al.
Published: (2020-01-01) -
Drugs approved by CDSCO, India in 2015
by: K Parushuram Naik1 , V Sai Lakshmi2 , J Jyothirmai3
Published: (2016-04-01) -
Political Institutions and the Legislative Success of Brazilian Presidents: an Analysis of the Cardoso, Lula and Rousseff Governments
by: Rodolfo Darrieux
Published: (2019-05-01)